PA5-34743

antibody from Invitrogen Antibodies

Targeting: CXCL9 CMK, crg-10, Humig, MIG, SCYB9

Western blot (Supportive data in Antibodypedia)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-34743

Provider

Invitrogen Antibodies

Product name

CXCL9 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

Recommended positive controls: A431.

Concentration

1.33 mg/mL

References

Submitted references

CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.

Seitz S, Dreyer TF, Stange C, Steiger K, Bräuer R, Scheutz L, Multhoff G, Weichert W, Kiechle M, Magdolen V, Bronger H
British journal of cancer 2022 Jun;126(10):1470-1480

---

KCNK3 Mutation Causes Altered Immune Function in Pulmonary Arterial Hypertension Patients and Mouse Models.

West JD, Austin ED, Rizzi EM, Yan L, Tanjore H, Crabtree AL, Moore CS, Muthian G, Carrier EJ, Jacobson DA, Hamid R, Kendall PL, Majka S, Rathinasabapathy A
International journal of molecular sciences 2021 May 9;22(9)

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of CXCL9 using 30 µg of A431 lysate. Samples were loaded onto a 12% SDS-PAGE gel and probed with a CXCL9 polyclonal antibody (Product # PA5-34743) at a dilution of 1:1500.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western Blot using CXCL9 Polyclonal Antibody (Product # PA5-34743). Untreated (–) and treated (+) MDA-MB-231 whole cell extracts (30 µg) were separated by 15% SDS-PAGE, and the membrane was blotted with CXCL9 Polyclonal Antibody (Product # PA5-34743) diluted at 1:1,000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

CXCL9 Polyclonal Antibody detects MIG protein at cytoplasm by immunofluorescent analysis. Sample: A431 cells were fixed in 4% paraformaldehyde at RT for 5 min. Green: MIG protein stained by CXCL9 Polyclonal Antibody (Product # PA5-34743) diluted at 1:1,000. Blue: Hoechst 33342 staining.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

CXCL9 Polyclonal Antibody detects MIG protein at cytoplasm by immunofluorescent analysis. Sample: A431 cells were fixed in 4% paraformaldehyde at RT for 5 min. Green: MIG protein stained by CXCL9 Polyclonal Antibody (Product # PA5-34743) diluted at 1:1,000. Blue: Hoechst 33342 staining.

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

CXCL9 Polyclonal Antibody detects CXCL9 protein at cytosol on human lung adenocarcinoma by immunohistochemical analysis. Sample: Paraffin-embedded lung adenocarcinoma. CXCL9 Polyclonal Antibody (Product # PA5-34743) dilution: 1:250. Antigen Retrieval: EDTA based buffer, pH 8.0, 15 min.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 6 IHC and CyTOF assessment on human tissue samples validate the role of inflammation in driving KCNK3-PAH. ( A ) Immunofluorescence depicting increased numbers CXCL9 + cells (red) in the KCNK3 patient lung, around the muscularized vessels (green), 400X magnification. ( B ) 2D density contour expression of mass immunotyping of KCNK3 PBMCs. ( C and D ) Naive T cells are downregulated in KCNK3 PBMCs, compensated through the upregulation of central and memory cells in CD4 + and CD8 + population. ( E and F ) CyTOF findings verify the role of cell mediated immune response in KCNK3 subjects through the dysregulation of CXCR3 + , CX3CR1 + , CCR4 + , CD127 + CD8 + and PD1 + CD8 + cells.